头孢菌素SM - 1652在小鼠、大鼠、兔子、狗和恒河猴体内的药代动力学。
Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys.
作者信息
Matsui H, Yano K, Okuda T
出版信息
Antimicrob Agents Chemother. 1982 Aug;22(2):213-7. doi: 10.1128/AAC.22.2.213.
Abstract
The pharmacokinetics of SM-1652 were studied in mice, rats, rabbits, dogs, and rhesus monkeys. The plasma half-lives of SM-1652, administered intravenously at a dose of 20 mg/kg, were 11.0 min in mice, 26.0 min in rats, 65.8 min in rabbits, 72.6 min in dogs, and 150.9 min in monkeys. The 24-h urinary excretion of SM-1652 was 30 to 35% of the dose in mice and rats, 70 to 75% in rabbits and dogs, and 45% in monkeys. Biliary excretion of the antibiotic over a 24-h period was 60 and 19% in rats and rabbits, respectively; it was 19% in dogs over a 9-h period after SM-1652 administration. Approximately 95% of the intravenous dose of SM-1652 was recovered as the unchanged form in the urine and bile of rats and rabbits. The binding of SM-1652 to serum protein was 44.0% in mice, 46.0% in rats, 90.4% in rabbits, 93.2% in monkeys, 30.0% in dogs, and 96.3% in humans.
摘要
在小鼠、大鼠、兔子、狗和恒河猴中研究了SM - 1652的药代动力学。以20mg/kg的剂量静脉给药后，SM - 1652在小鼠中的血浆半衰期为11.0分钟，在大鼠中为26.0分钟，在兔子中为65.8分钟，在狗中为72.6分钟，在猴子中为150.9分钟。SM - 1652在小鼠和大鼠中的24小时尿排泄量为剂量的30%至35%，在兔子和狗中为70%至75%，在猴子中为45%。在24小时内，抗生素在大鼠和兔子中的胆汁排泄量分别为60%和19%；在给SM - 1652后9小时内，狗的胆汁排泄量为19%。静脉注射剂量的SM - 1652中约95%以原形在大鼠和兔子的尿液和胆汁中回收。SM - 1652与血清蛋白的结合率在小鼠中为44.0%，在大鼠中为46.0%，在兔子中为90.4%，在猴子中为93.2%，在狗中为30.0%，在人类中为96.3%。
相似文献
1
Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys.头孢菌素SM - 1652在小鼠、大鼠、兔子、狗和恒河猴体内的药代动力学。
Antimicrob Agents Chemother. 1982 Aug;22(2):213-7. doi: 10.1128/AAC.22.2.213.
2
Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals.新型广谱头孢霉素YM09330经肠胃外给药于各种实验动物后的药代动力学
Antimicrob Agents Chemother. 1981 Aug;20(2):176-83. doi: 10.1128/AAC.20.2.176.
3
Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals.SCE - 2787及相关抗生素在实验动物中的比较药代动力学
Antimicrob Agents Chemother. 1992 Nov;36(11):2481-6. doi: 10.1128/AAC.36.11.2481.
4
Pharmacokinetics of ceftizoxime in animals after parenteral dosing.头孢唑肟经肠胃外给药后在动物体内的药代动力学。
Antimicrob Agents Chemother. 1980 Feb;17(2):157-64. doi: 10.1128/AAC.17.2.157.
5
Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys.
Antimicrob Agents Chemother. 1984 Aug;26(2):204-7. doi: 10.1128/AAC.26.2.204.
6
Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys.卡芦莫南和氨曲南在小鼠、大鼠、家兔、犬及食蟹猴体内的比较药代动力学。
Antimicrob Agents Chemother. 1986 Jan;29(1):127-34. doi: 10.1128/AAC.29.1.127.
7
Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.新型促甲状腺素释放激素类似物水合蒙替瑞林的药代动力学。首次通讯：对大鼠、狗和猴子单次静脉给药后的血浆浓度、代谢及排泄情况
Arzneimittelforschung. 1996 Feb;46(2):106-13.
8
Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals.新型喹诺酮类药物CP-74,667在实验动物中的药代动力学研究。
Antimicrob Agents Chemother. 1992 Aug;36(8):1671-6. doi: 10.1128/AAC.36.8.1671.
9
Pharmacokinetics of FK027 in rats and dogs.FK027在大鼠和犬体内的药代动力学。
J Antibiot (Tokyo). 1985 Apr;38(4):496-504. doi: 10.7164/antibiotics.38.496.
10
Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound.4-乙酰氨基苯乙酸的药代动力学。首次通讯：单次给予14C标记化合物后在小鼠、大鼠、狗和猴体内的吸收、分布、代谢及排泄情况
Arzneimittelforschung. 1990 Jul;40(7):800-5.
引用本文的文献
1
An in vivo role of Mrp2 in the rat hepatocytes by immunocytochemistry for amoxicillin using the transporter-deficient EHBR.利用转运体缺陷型 EHBR 通过免疫细胞化学法检测阿莫西林，鉴定 Mrp2 在大鼠肝细胞中的体内作用。
J Mol Histol. 2012 Jun;43(3):371-8. doi: 10.1007/s10735-012-9406-2. Epub 2012 Mar 25.
2
Immunocytochemistry for amoxicillin and its use for studying uptake of the drug in the intestine, liver, and kidney of rats.免疫细胞化学法检测阿莫西林及其在研究大鼠肠、肝、肾摄取该药物中的应用。
Antimicrob Agents Chemother. 2011 Jan;55(1):62-71. doi: 10.1128/AAC.01031-10. Epub 2010 Oct 25.
3
Predominant contribution of rat organic anion transporting polypeptide-2 (Oatp2) to hepatic uptake of beta-lactam antibiotics.大鼠有机阴离子转运多肽-2（Oatp2）对β-内酰胺类抗生素肝脏摄取的主要贡献。
Pharm Res. 2008 Mar;25(3):578-85. doi: 10.1007/s11095-007-9427-9. Epub 2007 Sep 22.
4
Quantitative evaluation of capacity-limited hepatobiliary transport based on hepatocellular diffusion model by MULTI(FEM).基于多物理场有限元法（MULTI(FEM)）的肝细胞扩散模型对容量受限肝胆转运的定量评估
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):415-44. doi: 10.1023/a:1012206330281.
5
Faropenem transport across the renal epithelial luminal membrane via inorganic phosphate transporter Npt1.法罗培南通过无机磷酸盐转运体Npt1跨肾上皮管腔膜转运。
Antimicrob Agents Chemother. 2000 Mar;44(3):574-7. doi: 10.1128/AAC.44.3.574-577.2000.
6
The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.从临床前结果推算至I期试验方案背后的药代动力学原理。
Clin Pharmacokinet. 1999 Jan;36(1):1-11. doi: 10.2165/00003088-199936010-00001.
7
New hepatocellular diffusion model for analysis of hepatobiliary transport processes of drugs.用于分析药物肝胆转运过程的新型肝细胞扩散模型。
J Pharmacokinet Biopharm. 1995 Apr;23(2):183-203. doi: 10.1007/BF02354271.
8
Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice.新型胃肠外头孢菌素头孢唑兰（SCE - 2787）对小鼠实验性感染的治疗效果
Antimicrob Agents Chemother. 1993 Jan;37(1):100-5. doi: 10.1128/AAC.37.1.100.
9
Biliary and renal excretions of cefpiramide in Eisai hyperbilirubinemic rats.头孢匹胺在卫材高胆红素血症大鼠体内的胆汁和肾脏排泄情况。
Antimicrob Agents Chemother. 1995 Jan;39(1):70-4. doi: 10.1128/AAC.39.1.70.
10
Pharmacokinetics of cefpiramide (SM-1652) in humans.头孢匹胺（SM-1652）在人体内的药代动力学。
Antimicrob Agents Chemother. 1984 Feb;25(2):221-5. doi: 10.1128/AAC.25.2.221.
本文引用的文献
1
Pharmacological and toxicological studies on cephalotin.头孢噻吩的药理与毒理学研究
Clin Med (Northfield). 1963 Jun;70:1123-38.
2
Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.头孢雷特（BL-S786R）与头孢唑林在实验动物和人体中的比较药代动力学。
Antimicrob Agents Chemother. 1980 Feb;17(2):188-92. doi: 10.1128/AAC.17.2.188.
3
Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals.新型广谱头孢霉素YM09330经肠胃外给药于各种实验动物后的药代动力学
Antimicrob Agents Chemother. 1981 Aug;20(2):176-83. doi: 10.1128/AAC.20.2.176.
4
Pharmacokinetics of ceftizoxime in animals after parenteral dosing.头孢唑肟经肠胃外给药后在动物体内的药代动力学。
Antimicrob Agents Chemother. 1980 Feb;17(2):157-64. doi: 10.1128/AAC.17.2.157.
5
Comparative pharmacokinetics and metabolism of cephapirin in laboratory animals and humans.头孢匹林在实验动物和人类中的比较药代动力学与代谢
Antimicrob Agents Chemother. 1976 Aug;10(2):307-17. doi: 10.1128/AAC.10.2.307.
6
Metabolic fate of cephacetrile after parenteral administration in rats and rabbits.
J Antibiot (Tokyo). 1976 Jan;29(1):81-90. doi: 10.7164/antibiotics.29.81.
7
Pharmacokinetics of cefotaxime.头孢噻肟的药代动力学。
Antimicrob Agents Chemother. 1979 Nov;16(5):592-7. doi: 10.1128/AAC.16.5.592.
8
SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.SK&F 75073，一种新型肠胃外使用的广谱头孢菌素，血清浓度高且持续时间长。
Antimicrob Agents Chemother. 1978 May;13(5):784-90. doi: 10.1128/AAC.13.5.784.
Zotero 插件